BioNTech
NEWS
Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.
The new authorization is expected to be the final reassurance for many of those who had hesitated when the vaccine was approved under emergency use only.
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu.
Many expect the full approval will lead to vaccine mandates, as that was one of the obstacles to it for many organizations.
It was another busy week in clinical trial news. Here’s a look.
A J&J spokesperson said yesterday that it is collecting more data on whether a booster shot is necessary.
As COVID-19 surges to earlier pandemic levels in the U.S., federal health officials are expected to authorize a third booster shot eight months after receiving the second of the Moderna and Pfizer-BioNTech vaccines, and probably the Johnson & Johnson vaccine as well.
The amended EUA is aimed at patients who have undergone solid organ transplants or those diagnosed with conditions that have an “equivalent level of immunocompromised.”
Citing a study from Johns Hopkins University, researchers found that immunocompromised people are 485 times more likely to end up in the hospital or die from COVID-19.
JOBS
IN THE PRESS